- Home
- HRMY vs GABC Comparison
HRMY vs GABC Comparison
Compare HRMY & GABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | GABC |
|---|---|---|
| Founded | 2017 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | HRMY | GABC |
|---|---|---|
| Price | $36.75 | $49.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $48.08 | ★ $56.40 |
| AVG Volume (30 Days) | ★ 993.4K | 131.4K |
| Earning Date | 11-04-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 2.50% |
| EPS Growth | 7.97 | ★ 8.13 |
| EPS | 1.84 | ★ 1.90 |
| Revenue | ★ $868,453,000.00 | $487,401,000.00 |
| Revenue This Year | $18.17 | $11.03 |
| Revenue Next Year | $13.71 | $5.22 |
| P/E Ratio | ★ $20.01 | $26.14 |
| Revenue Growth | 21.51 | ★ 37.80 |
| 52 Week Low | $25.90 | $37.73 |
| 52 Week High | $43.49 | $52.23 |
Technical Indicators
Market Signals| Indicator | HRMY | GABC |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 51.90 |
| Support Level | $36.74 | $47.90 |
| Resistance Level | $39.40 | $51.98 |
| Average True Range (ATR) | 1.50 | 1.17 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 80.36 | 41.02 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About GABC German American Bancorp Inc.
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.